PTGFRN and cancer: This makes PTGFRN a valuable target for ADC development, as it is preferentially expressed in certain cancers compared to non‐cancerous tissue, it can act as a biomarker to predict response and stratify patients, and is found to be overexpressed when certain cancers become metastatic [24].